Taysha Gene Therapies Inc (TSHA) concluded trading on Wednesday at a closing price of $2.67, with 7.89 million shares of worth about $21.07 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 7.66% during that period and on June 11, 2025 the price saw a gain of about 2.30%. Currently the company’s common shares owned by public are about 261.53M shares, out of which, 213.50M shares are available for trading.
Stock saw a price change of -4.30% in past 5 days and over the past one month there was a price change of 15.09%. Year-to-date (YTD), TSHA shares are showing a performance of 54.34% which decreased to -32.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.05 but also hit the highest price of $4.32 during that period. The average intraday trading volume for Taysha Gene Therapies Inc shares is 3.43 million. The stock is currently trading -2.02% below its 20-day simple moving average (SMA20), while that difference is up 27.20% for SMA50 and it goes to 35.59% higher than SMA200.
Taysha Gene Therapies Inc (NASDAQ: TSHA) currently have 261.53M outstanding shares and institutions hold larger chunk of about 62.25% of that.
The stock has a current market capitalization of $698.29M and its 3Y-monthly beta is at 1.01. It has posted earnings per share of -$0.36 in the same period. It has Quick Ratio of 5.35 while making debt-to-equity ratio of 1.13. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TSHA, volatility over the week remained 3.84% while standing at 4.73% over the month.
Stock’s fiscal year EPS is expected to rise by 12.04% while it is estimated to decrease by -18.28% in next year. EPS is likely to grow at an annualized rate of 11.06% for next 5-years, compared to annual growth of -63.99% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BMO Capital Markets on June 27, 2024 offering an Outperform rating for the stock and assigned a target price of $5 to it. Coverage by Piper Sandler stated Taysha Gene Therapies Inc (TSHA) stock as an Overweight in their note to investors on April 09, 2024, suggesting a price target of $9 for the stock. On February 01, 2023, Jefferies Downgrade their recommendations, while on January 27, 2023, Morgan Stanley Downgrade their ratings for the stock with a price target of $3. Stock get a Neutral rating from Goldman on November 09, 2022.
